AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director
AIM ImmunoTech (NYSE American: AIM) has appointed David Chemerow as an Independent Director to its Board of Directors, effective immediately. Chemerow brings over 40 years of finance, accounting, and operations leadership experience to the role.
Chemerow previously served as CFO, Treasurer, and Chief Revenue Officer at Comscore, and as COO and CFO of Rentrak until its 2016 merger with Comscore. He currently serves on the Board of Directors for Dunham's Athleisure and the Advisory Board of Huntington Outdoor.
The appointment was unanimously approved by AIM's Board. Board Chairman William Mitchell highlighted Chemerow's proven track record of leadership and financial acumen as valuable additions to AIM's mission. Chemerow expressed optimism about AIM's position in the immuno-pharma space, particularly noting Ampligen's potential across various high-value indications.
AIM ImmunoTech (NYSE American: AIM) ha nominato David Chemerow come Direttore Indipendente del suo Consiglio di Amministrazione, con effetto immediato. Chemerow porta con sé oltre 40 anni di esperienza nella leadership finanziaria, contabile e operativa nel ruolo.
Chemerow ha precedentemente ricoperto i ruoli di CFO, Tesoriere e Chief Revenue Officer presso Comscore, e di COO e CFO di Rentrak fino alla sua fusione con Comscore nel 2016. Attualmente, fa parte del Consiglio di Amministrazione di Dunham's Athleisure e del Consiglio Consultivo di Huntington Outdoor.
La nomina è stata approvata all'unanimità dal Consiglio di AIM. Il Presidente del Consiglio, William Mitchell, ha sottolineato il comprovato track record di leadership e competenza finanziaria di Chemerow come preziosi contributi alla missione di AIM. Chemerow ha espresso ottimismo riguardo alla posizione di AIM nel settore immuno-farmaceutico, notando in particolare il potenziale di Ampligen in diverse indicazioni di alto valore.
AIM ImmunoTech (NYSE American: AIM) ha nombrado a David Chemerow como Director Independiente de su Junta Directiva, con efecto inmediato. Chemerow aporta más de 40 años de experiencia en liderazgo financiero, contable y operativo al cargo.
Chemerow se desempeñó anteriormente como CFO, Tesorero y Chief Revenue Officer en Comscore, y como COO y CFO de Rentrak hasta su fusión con Comscore en 2016. Actualmente, forma parte de la Junta Directiva de Dunham's Athleisure y del Consejo Asesor de Huntington Outdoor.
La nominación fue aprobada por unanimidad por la Junta de AIM. El Presidente de la Junta, William Mitchell, destacó el historial comprobado de liderazgo y agudeza financiera de Chemerow como valiosas adiciones a la misión de AIM. Chemerow expresó optimismo sobre la posición de AIM en el espacio inmuno-farmacéutico, señalando en particular el potencial de Ampligen en diversas indicaciones de alto valor.
AIM ImmunoTech (NYSE American: AIM)는 David Chemerow를 이사회 독립 이사로 즉시 임명했습니다. Chemerow는 40년 이상의 재무, 회계 및 운영 리더십 경험을 이 역할에 가져옵니다.
Chemerow는 이전에 Comscore에서 CFO, 재무 담당 이사 및 수익 최고 책임자로 재직했으며, Rentrak의 COO 및 CFO로 활동하다 2016년 Comscore와 합병되었습니다. 현재 그는 Dunham's Athleisure 이사회와 Huntington Outdoor 자문위원회에서 활동하고 있습니다.
이 임명은 AIM 이사회에서 만장일치로 승인되었습니다. 이사회 의장인 William Mitchell은 Chemerow의 입증된 리더십과 재무적 통찰력이 AIM의 사명에 귀중한 추가 요소라고 강조했습니다. Chemerow는 AIM의 면역-제약 분야에서의 입장에 대해 낙관적인 입장을 표명하며, 특히 Ampligen의 다양한 고부가가치 적응증에서의 잠재력을 언급했습니다.
AIM ImmunoTech (NYSE American: AIM) a nommé David Chemerow en tant que Directeur Indépendant de son Conseil d'Administration, avec effet immédiat. Chemerow apporte plus de 40 ans d'expérience en leadership financier, comptable et opérationnel à ce poste.
Chemerow a précédemment été CFO, Trésorier et Chief Revenue Officer chez Comscore, et COO et CFO de Rentrak jusqu'à sa fusion avec Comscore en 2016. Il siège actuellement au Conseil d'Administration de Dunham's Athleisure et au Conseil Consultatif de Huntington Outdoor.
La nomination a été approuvée à l'unanimité par le Conseil d'AIM. Le Président du Conseil, William Mitchell, a souligné le parcours éprouvé de leadership et de compétence financière de Chemerow comme des ajouts précieux à la mission d'AIM. Chemerow a exprimé son optimisme quant à la position d'AIM dans le domaine de l'immuno-pharmaceutique, notant en particulier le potentiel d'Ampligen dans diverses indications à forte valeur ajoutée.
AIM ImmunoTech (NYSE American: AIM) hat David Chemerow mit sofortiger Wirkung zum Unabhängigen Direktor des Vorstands ernannt. Chemerow bringt über 40 Jahre Erfahrung in der Führung von Finanzen, Buchhaltung und Betrieb in diese Rolle ein.
Chemerow war zuvor CFO, Schatzmeister und Chief Revenue Officer bei Comscore und COO sowie CFO von Rentrak bis zur Fusion mit Comscore im Jahr 2016. Derzeit ist er Mitglied des Vorstands von Dunham's Athleisure und im Beratergremium von Huntington Outdoor.
Die Ernennung wurde einstimmig vom Vorstand von AIM genehmigt. Der Vorstandsvorsitzende William Mitchell hob Chemerows nachgewiesene Führungskompetenz und finanzielle Klugheit als wertvolle Ergänzungen zur Mission von AIM hervor. Chemerow äußerte Optimismus über die Position von AIM im immuno-pharmazeutischen Bereich und hob insbesondere das Potenzial von Ampligen in verschiedenen hochpreisigen Indikationen hervor.
- Board strengthened with 40+ years of financial and operational expertise
- Unanimous board approval indicates strong internal alignment
- New director brings valuable public company CFO experience
- None.
OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Company’s Board of Directors (the “Board”) has, by unanimous vote, appointed David Chemerow as an Independent Director to the Board, effective immediately.
Mr. Chemerow brings more than 40 years of finance, accounting and operations leadership experience across multiple industries. He previously served as the Chief Financial Officer and Treasurer, and prior to that as Chief Revenue Officer, of Comscore, Inc., an American-based global media measurement and analytics company. Prior to his tenure at Comscore, Mr. Chemerow served as the Chief Operating Officer and Chief Financial Officer of Rentrak Corporation through its merger with Comscore, Inc. in January 2016. Prior to 2009, Mr. Chemerow held senior executive roles leveraging his financial, business and operational expertise across multiple companies.
Mr. Chemerow currently serves on the Board of Directors for Dunham’s Athleisure Corporation, a sporting goods retailer, and on the Advisory Board of Huntington Outdoor, LLC, an outdoor advertising company. Additionally, Mr. Chemerow serves on the Board of non-profit theater, The Martha’s Vineyard Playhouse, and is President of the Board of the Pilot Hill Farm Association. Previously, Mr. Chemerow served as a member of the Board of Directors of RiceBran Technologies, Inc., a Nasdaq and OTC company, and served 15 years as a Board member of Playboy Enterprises. Mr. Chemerow is a graduate of Dartmouth College and holds a Master of Business Administration degree from The Amos Tuck School at Dartmouth College.
AIM Board of Directors Chairman William Mitchell, MD, PhD, stated: “Mr. Chemerow has a proven track record of leadership, business and financial acumen over the course of his career. His skills, experiences and qualifications will be valuable contributions to AIM’s mission as we continue to advance toward near-and long-term success. I look forward to working with him.”
Mr. Chemerow added: “I believe AIM is well positioned to be a valuable player in the immuno-pharma space. Ampligen has demonstrated potential across a number of high-value indications, and I am excited to help propel the Company to its next phase of growth.”
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a prophylactic or therapy for any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ae8dd177-5ac1-48be-8138-8431c866af4a
FAQ
What experience does David Chemerow bring to AIM ImmunoTech's Board?
When did AIM ImmunoTech appoint David Chemerow to its Board?
What are David Chemerow's current board positions besides AIM?
What is Chemerow's perspective on AIM's market position?
